Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Шайэр ЛлсfiledCriticalШайэр Ллс
Publication of UA87812C2publicationCriticalpatent/UA87812C2/en
Acyclic And Carbocyclic Compounds In Medicinal Compositions
(AREA)
Medicinal Preparation
(AREA)
Abstract
A pharmaceutical composition comprises a once-a-day sustained release formulation of at least one amphetamine salt which provides mean plasma concentration profile aspects in human ADHD patients which are substantially the same as that provided by ADDERALL XRtype pulsatile formulations.
UAA200503845A2002-09-242003-09-24Sustained release formulation of amphetamine salts
UA87812C2
(en)
fostamatinib or a pharmaceutically acceptable salt of fostamatinib, or a hydrate, solvate or N-oxide of fostamatinib or the pharmaceutically acceptable salt of fostamatinib, in particular fostamatinib disodium, optionally in the form of a hydrate